Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025

Rhea-AI Summary

Vivoryon Therapeutics (Euronext: VVY) will publish its Q3 2025 financial results and provide an operational update on December 4, 2025. The company will host a public conference call and live webcast at 3:00 pm CET / 9:00 am EST to discuss results and corporate developments.

Investors can access the live audio webcast on the company's investor site and join the call by pre-registering for phone dial-in details. Attendees are advised to dial in 15 minutes before the scheduled start to avoid delays.

Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025

Halle (Saale) / Munich, Germany, November 25, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that it will publish its third quarter financial results for the period ended September 30, 2025 and provide a corporate update on Thursday, December 4, 2025. The Company will host a conference call and webcast open to the public.

Conference call details
Date: December 4, 2025
Time: 3:00 pm CET / 9:00 am EST

The conference call will be available via phone and webcast.
The live audio webcast of the call will be available on Vivoryon´s website at: https://www.vivoryon.com/news-and-events/presentations-webcasts/

To join the conference call via phone, participants may pre-register and will receive dedicated dial-in details to easily and quickly access the call via the following website:
https://register-conf.media-server.com/register/BI375e056b91ee4184ab17c7212371dfda

It is suggested participants dial into the conference call 15 minutes prior to the scheduled start time to avoid any delays in attendance.

###

About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. www.vivoryon.com

Vivoryon Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.

For more information, please contact:

Investor Contacts
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email: IR@vivoryon.com

LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email: svonderweid@lifesciadvisors.com

Media Contact
Trophic Communications
Valeria Fisher or Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email: vivoryon@trophic.eu

Attachment

• 20251125_Q3 2025 NoR

FAQ

When will Vivoryon (VVY) release Q3 2025 financial results?

Vivoryon will publish its Q3 2025 financial results on December 4, 2025.

What time is Vivoryon VVY's Q3 2025 conference call and webcast?

The conference call and webcast are scheduled for 3:00 pm CET / 9:00 am EST on December 4, 2025.

How can investors access the Vivoryon (VVY) Q3 2025 webcast?

The live audio webcast will be available on Vivoryon's investor website under Presentations & Webcasts.

How do I join Vivoryon VVY's conference call by phone?

Pre-register via the provided registration page to receive dedicated dial-in details for the phone conference.

Will Vivoryon (VVY) discuss clinical and operational progress during the Q3 2025 call?

Yes; the company said it will provide an operational update alongside the Q3 2025 financial results during the call.

When should attendees dial in for the Vivoryon VVY Q3 2025 call to avoid delays?

Attendees are advised to dial in 15 minutes before the scheduled start time.